AKTS – Akoustis Technologies Inc
Aktis Oncology, Inc. Common stockAKTS
$0.037Name : Akoustis Technologies, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,953,828.00
EPSttm : -1.16
Aktis Oncology, Inc. Common stock
$0.037
0.00%$0.037Float Short %
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.04
EPS Last/This Y
1.44
EPS This/Next Y
0.25
Price
0.04
Target Price
Analyst Recom
Performance Q
Relative Volume
Beta
Ticker: AKTS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-11 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2025-12-12 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2025-12-15 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2025-12-16 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2025-12-17 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2025-12-18 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2025-12-19 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2025-12-22 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2025-12-23 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2025-12-26 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2025-12-29 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2025-12-30 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2025-12-31 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2026-01-02 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2026-01-05 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2026-01-06 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2026-01-07 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2026-01-08 | AKTS | 0.0372 | N/A | N/A | 0 |
| 2026-01-09 | AKTS | 21.22 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
No data found
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-09 | AKTS | 0 | 0 | 0 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.04
Avg. EPS Est. Current Quarter
-0.07
Avg. EPS Est. Next Quarter
-0.07
Insider Transactions
Institutional Transactions
Beta
Average Sales Estimate Current Quarter
9
Average Sales Estimate Next Quarter
10
Fair Value
Quality Score
54
Growth Score
48
Sentiment Score
13
Actual DrawDown %
99.8
Max Drawdown 5-Year %
-99.8
Target Price
P/E
Forward P/E
PEG
P/S
P/B
P/Free Cash Flow
EPS
Average EPS Est. Cur. Y
-0.45
EPS Next Y. (Est.)
-0.2
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
Return on Equity vs Sector %
183.5
Return on Equity vs Industry %
216.6
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.09
EBIT Estimation
Akoustis Technologies, Inc.Sector: Healthcare
Industry: Biotechnology
Employees:
Aktis Oncology, Inc. develops and manufactures precision radiopharmaceutical therapies for cancer treatment. The company focuses on solid tumors with limited treatment options, engineering targeted therapies that utilize alpha-emitting particles to deliver cancer-killing effects while minimizing exposure to healthy tissue. It employs a theranostic approach, using imaging tools to visualize and verify tumor targeting, and to predict patient response. The company manages logistics and just-in-time delivery of its radiopharmaceuticals to ensure timely administration. Aktis Oncology serves healthcare providers and medical professionals involved in cancer treatment. The company was founded in 2020 and is based in Boston, Massachusetts.
stock quote shares AKTS – Akoustis Technologies Inc Stock Price stock today
news today AKTS – Akoustis Technologies Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch AKTS – Akoustis Technologies Inc yahoo finance google finance
stock history AKTS – Akoustis Technologies Inc invest stock market
stock prices AKTS premarket after hours
ticker AKTS fair value insiders trading